NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the Regen Med Partnering Forum during the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16. Mr. McGlynn is scheduled to speak at 11:00 a.m. Pacific Time on Monday, October 14, at the Estancia La Jolla Hotel in La Jolla, Calif. A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine's (ARM) website shortly after the event.
The Stem Cell Meeting on the Mesa is a three-day conference organized by the Sanford Consortium for Regenerative Medicine, the California Institute for Regenerative Medicine (CIRM), and ARM. The conference brings together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The first two days of the conference, October 14-15, features the Regen Med Partnering Forum, the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. The conference also features a nationally recognized Scientific Symposium, which is attended by leading scientists and researchers and will showcase leading academic research in the field of regenerative medicine. Please visit http://stemcellmeetingonthemesa.com/ for more information.
StemCells, Inc. is a sponsor of the 2013 Stem Cell Meeting on the Mesa.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's proprietary HuCNS-SC® cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first three patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of the Company's HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Rodney Young
Chief Financial Officer